To determine the risks when the primary methotrexate (MTX) treatment of cervical pregnancy has an unsatisfactory outcome, we conducted a Medline search on relevant literature published from January 1983 to June 1997. The search yielded 28 publications of 48 cases of cervical pregnancy. These and four new cases from our institutions were used in our study. A cervical pregnancy that presented with a serum β-human chorionic gonadotrophin concentration of ജ10 000 mIU/ml [odds ratio (OR) 10.82, 95% confidence interval (CI) 2.59, 45.14], gestational age at ജ9 weeks (OR 6.44, 95% CI 1.46, 28.52), embryonic cardiac activity (OR 14.29, 95% CI 2.95, 76.92), and crown-rump length of Ͼ10 mm (OR 13.33, 95% CI 1.46, 120.48) was considered to be associated with a higher unsatisfactory rate of primary MTX treatment. A concomitant feticide was found to enhance the therapeutic effect of MTX treatment if embryonic cardiac activity was evident (OR 0.13, 95% CI 0.02, 0.68). Administration of a high dose of MTX did not seem to be more effective than a lower one. Our findings supported some previous observations and, more importantly, provided useful clinical information in selecting appropriate candidates for MTX treatment in cases of cervical pregnancy.
Introduction
Methotrexate (MTX) treatment, administered either systemically or locally, has been reported to be an effective definitive therapy to preserve potential fertility in a patient with cervical pregnancy (Oyer et al., 1988; Stovall et al., 1988; Kaplan et al., 1989; Yankowitz et al., 1990; Timor-Tritsch et al., 1994; Hung et al., 1996) . However, some authors claimed that their cases failed initial MTX treatment and required additional interventions, including suction curettage (Timor-Tritsch et al., 1994; Mantalenakis et al., 1995) , salvage chemotherapy with the same agent (Kaplan et al., 1990; Chao et al., 1993; Hsu et al., 1995; Hung et al., 1996) , feticide with intra-amniotic injection of potassium chloride (Ginsburg et al., 1994; Kung et al., 1995) , angiographic embolization (Marston et al., 1996; Cosin et al., 1997) or ligation of bilateral uterine arteries via laparotomy (Wolcott et al., 1988) , and even hysterectomy (Dall et al., 1994; Kaminopetros et al., 1996) .
The incidence of cervical pregnancy is rare, and thus it is impractical to perform a prospective, randomized, controlled study to evaluate the efficacy of the different therapeutic regimens of MTX treatment. Furthermore, no study has yet been reported that analyses quantitatively the risk factors associated with the failure of primary MTX treatment. Recently, we encountered four such cases and this cluster of cases stimulated us to conduct an investigation based on an extensive literature search of reported cases. We conducted a quantitative review using our cases and the cases from the literature search to identify the clinical factors that might lead to an unsatisfactory outcome of primary MTX treatment in cases of cervical pregnancy.
Materials and methods
The CD-Plus Medline Ovid system (Ovid Technologies Inc., New York, NY, USA) was used to search for English language literature published from January 1983 to June 1997 related to cervical pregnancy and its diagnosis and management. Medical subject heading key words included 'pregnancy', 'ectopic', 'uterine cervix', and 'methotrexate'. We chose 1983 as a starting point for the literature search because this year was marked by a pioneer publication by Farabow et al. (1983) on the use of MTX for the treatment of cervical pregnancy.
From the authors' descriptions of individual case reports, we culled the available and reliable information for the possible predisposing factors, clinical presentation, and management. Only published reports involving MTX treatment were included in the analyses. Cases that were initially manipulated by any surgical procedure prior to MTX administration, with a simultaneous intrauterine pregnancy, treated with a combination of other chemotherapeutic agents, or without a detailed description of the case were excluded. To check for selection bias, comparisons were performed between the selected publications and the cases that were excluded or not related to MTX treatment for the distribution of the locations of the institutions and the journals where the article originated. The geographic distribution was divided into America, Europe, Asia-Oceania (including Middle East, Australia and New Zealand), and Africa. The journals were ranked according to the impact factor from the Journal Citation Reports on CD-ROM, 1996 (Institution for Scientific Information, Philadelphia, PA, USA).
An unsatisfactory result was defined as a rise or plateau of serum β-human chorionic gonadotrophin (HCG) concentration beyond 7 days after initial MTX treatment, uncontrollable vaginal bleeding, or a persistent cervical gestational mass with or without embryonic cardiac activity developing during the period of follow-up and requiring an additional therapeutic intervention.
Prognostic factors for analysis included age, gravidity, prior history of dilatation and curettage, prior history of Caesarean section, conception method, serum β-HCG concentrations before treatment, gestational age at presentation, evident embryonic cardiac activity before treatment, size of the gestational sac or crown-rump length if described, and regimen of MTX administration. If embryonic cardiac activity was present, feticide by intracardiac injection of potassium chloride, intra-amniotic instillation of MTX or direct traumatic punctures to cease the cardiac activity under sonographic guidance as a part of primary MTX treatment was also considered individually as a prognostic factor for investigation. Four new cases, which included three that failed initial MTX therapy from our institutions, were added to this analysis.
In view of the lack of uniformity in the MTX treatment, the therapeutic effects of the different regimens were estimated separately and arbitrarily according to the dose (high dose or low dose) and route of MTX administration (systemic administration, local injection or a combination of local and systemic administration) after controlling the factors that had a significant bivariate association with the result of primary MTX treatment. A high dose regimen referred to protocols containing MTX of 1 mg/kg four times every other day or a single dose of 300 mg/m 2 with folinic acid rescue, or a total dose Ͼ150 mg throughout the whole course of chemotherapy. On the other hand, a low dose regimen referred to a protocol consisting of a dose of ഛ150 mg. A local injection can be either by intra-amniotic or intracervical administration of the chemotherapeutic agent.
The statistical tests performed included χ 2 -test and multiple logistic regression using SPSS for Windows, Release 7.0 (Statistical Package for Social Sciences Inc., Chicago, IL, USA) and StatXact-3 (Cytel Software Corporation, Cambridge, MA, USA). Odds ratios (OR) and 95% confidence intervals (CI) were calculated when appropriate. Values of P Ͻ 0.05 were considered statistically significant.
Results
Our literature search produced 100 reports or articles related to cervical pregnancy published between January 1983 and June 1997. Of these, 42 were related to MTX treatment. Fourteen publications were further excluded because the cases were manipulated by a surgical procedure prior to MTX administration (n ϭ 5), occurred with a simultaneous intrauterine pregnancy (n ϭ 3), treated with a combination of other chemotherapeutic agents (n ϭ 2), and had no detailed case presentation (n ϭ 4). Thus, a total of 28 publications of 52 cases of cervical pregnancy including four additional new cases from our institutions were analysed. Table I shows the results of comparisons in geographic and journal distribution between the publications we analysed (n ϭ 28) and those that were excluded or not related to MTX treatment (n ϭ 72) during the same period we searched. No significant differences were found according to either geographic distribution or journal ranking between the articles we selected for analysis and those we did not. Table II summarizes the patients' characteristics, clinical presentation, concomitant regimens and the results of primary MTX treatment, and the additional intervention in the case of an unsatisfactory result. There was no significant difference in the mean (Ϯ SD) age (30.8 Ϯ 7.6 and 30.4 Ϯ 6.0 years, P ϭ 0.84), mean Ϯ SD gravidity (2.9 Ϯ 2.0, 3.0 Ϯ 1.4, P ϭ 0.83), Mean Ϯ SD maximal diameter of the gestational sac (10.9 Ϯ 3.6, 24.8 Ϯ 9.4 mm, P ϭ 0.38), or crown-rump JCR ϭ Journal Citation Reports, 1996. There were no significant differences based on χ 2 -test.
length (6.0 Ϯ 4.5, 15.2 Ϯ 9.2 mm, P ϭ 0.09) between patients with and without a satisfactory result. However, women with an unsatisfactory result of primary MTX treatment presented at later gestational weeks compared with those who were satisfactorily treated (8.5 Ϯ 2.3 and 7.1 Ϯ 1.6 weeks respectively, P Ͻ 0.05).
The overall satisfactory rate of primary MTX treatment was 61.5% (32/52) and 90.9% (20/22) and 40% (12/30) for a cervical pregnancy without or with embryonic cardiac activity, respectively. A total of 20 cases failed primary MTX treatment. The causes for additional interventions included massive or uncontrollable bleeding (n ϭ 6, Wolcott et al., 1988; Kaminopetros et al., 1996; Marston et al., 1996; Cosin et al., 1997 and our new cases), rise or plateau of serum β-HCG level (n ϭ 6, Kaplan et al., 1990; Ginsburg et al., 1994; Timor-Tritsch et al., 1994; Hsu et al., 1995; Mantalenakis et al., 1995; Kaminopetros et al., 1996) , persistent cervical ectopic gestation (n ϭ 7, Wolcott et al., 1988; Palti et al., 1989; Chao et al., 1993; Dall et al., 1994; and our new cases) and appearance or persistence of embryonic cardiac activity (n ϭ 7, Kaplan et al., 1990; Ginsburg et al., 1994; Kung et al., 1995; Mantalenakis et al., 1995; Hung et al., 1996; Kaminopetros et al., 1996 ; and our new case) during the period of follow-up. Some patients experienced more than one of these conditions. Fifteen patients were successfully treated to preserve their potential fertility with one additional therapeutic modality. These included further systemic MTX administration (n ϭ 5, Chao et al., 1993; Hsu et al., 1995;  and our new cases), intra-amniotic instillation of MTX (n ϭ 2, Kaplan et al., 1990; Hung et al., 1996) , feticide with intracardiac injection of potassium chloride (n ϭ 2, Ginsburg et al., 1994; Kung et al., 1995) , dilatation and curettege (n ϭ 3, Palti et al., 1989; Timor-Tritsch et al., 1994; Mantalenakis et al., 1995) , angiographic embolization of bilateral uterine arteries (n ϭ 1, Cosin et al., 1997) and conservative abdominal surgery (n ϭ 2, Wolcott et al., 1988 ; and our new case). Five patients needed more than one additional intervention; three out of the five underwent hysterectomy due to uncontrollable bleeding from the implantation site (Dall et al., 1994; Kaminopetros et al., 1996 ; and our new case). Table III summarizes the results of the bivariate analyses including the unsatisfactory rate according to the potential prognostic determinants under study. Patients who presented with a gestational age of ജ9 weeks (OR 6.44, 95% CI 1.46, 28.52), a serum β-HCG concentration of ജ10 000 mIU/ml (OR 10.82, 95% CI 2.59, 45.14), embryonic cardiac activity (OR 14.29, 95% CI 2.95, 76.92), and a crown-rump length Ͼ10 mm (OR 13.33, 95% CI 1.46, 120.48) were significantly associated with an increased risk for an unsatisfactory primary MTX treatment. On the other hand, concomitant performance of feticide was inversely associated with an unsatisfactory result (OR 0.13, 95% CI 0.02, 0.68). Variables that did not reach statistical significance included number of dilatation and curettage procedures and Caesarean sections, conception method, and the maximal diameter of the gestational sacs.
An attempt to control the mutually confounding effects of the risk factors in evaluating the therapeutic effects of the different regimens of MTX treatment was made by entering factors that had a significant bivariate association with an unsatisfactory result into a multivariate logistic regression analysis. The results are shown in Table IV . A high dose protocol did not seem to offer a better therapeutic response than a low dose protocol (adjusted OR 1.05, P ϭ 0.97). Patients who underwent systemic administration of MTX tended to respond satisfactorily, although this was not statistically significant, compared with those who were administered 2639 local injection or a combination of both methods (adjusted OR 2.94 and 724.00, P ϭ 0.43 and 0.80 respectively).
We further compared the data from our own experience with 15 patients with that from the 37 cases of the reviewed publications by a homogeneity test of odds ratios for stratified 2ϫ2 tables using an exact method. For factors that were found to have a significant effect on the result of primary MTX treatment in pooled data, the homogeneity test did not reveal any significant difference of odds ratios between these two subsets of data. That is, the associations were consistent within these two data sets. However, the sample size of our own series was too small to reveal any reliable analysis results.
Discussion
Although our series of published cases of cervical pregnancies treated with MTX (Hung et al., 1996) was the largest, there were still difficulties in evaluating the prognostic factors for primary MTX treatment and comparing the therapeutic effects of the different regimens because of its rarity. In the current study, with the pooled data derived from the literature review and our own cases, we demonstrated that for patients with cervical pregnancies, a gestational age of ജ9 weeks, serum β-HCG concentration of ജ10 000 mIU/ml, a crown-rump length Ͼ10 mm and embryonic cardiac activity were significantly associated with an increased risk of an unsatisfactory a Adjusted logistic regression model including a serum β-human chorionic gonadotrophin level of ജ10 000 mIU/ml, a gestational age at ജ9 weeks, evident embryonic cardiac activity, concomitant performance of feticide and a crown-rump length Ͼ10 mm.
result of primary MTX treatment. Previous reports have stated that a cervical pregnancy with evident embryonic cardiac activity (Spitzer et al., 1997) , structural fetal elements (Ory et al., 1986) , a serum β-HCG concentration Ͼ10 000 mIU/ml (Van de Meerssche et al., 1995) or a menstrual age Ͼ12 weeks (Kung et al., 1997) were more resistant to MTX treatment. However, their presumptions were arbitrary and based on sporadic case reports or experience of tubal ectopic pregnancy, instead of a statistical analysis with sizeable samples of cervical pregnancy. To our knowledge, the current study is the first to report and investigate the prognostic factors for the result of primary MTX treatment. Our findings support some previous observations and, more importantly, provide useful clinical information in selecting appropriate candidates for MTX treatment in cases of cervical pregnancy. Recently, Sieck et al. (1997) reported a cervical pregnancy that presented at nearly 7 weeks gestation with evident embryonic cardiac activity and a high serum β-HCG concentration of 170 000 mIU/ml. The patient responded unsatisfactorily to initial systemic administration of MTX (1 mg/kg/day), which was alternated with folinic acid rescue; she was, however, still managed successfully with another i.m. bolus of 70 mg of MTX. This case further supported our observations. Therefore, it is necessary to inform patients, especially those whom we demonstrated to be associated with risk factors, about the possibility of performing a repeated dose of MTX or other adjuvant therapy before the commencement of MTX treatment.
The incidence of cervical pregnancy is so rare that it is impractical to perform a prospective randomized study to evaluate the efficacy of different regimens of MTX treatment. Nevertheless, our analysis demonstrated that the administration of a higher dose of MTX appeared not to offer a more effective response than a lower dose. The side-effects associated with systemic MTX treatment include bone marrow depression, stomatitis, anorexia, nausea, vomiting, and diarrhoea (Floridon and Thomsen, 1994) . High doses can cause significant myelosuppression, acute and chronic hepatotoxicity, pulmonary fibrosis, alopecia, and photosensitivity (Carson and Buster, 1993) . Although these side-effects are infrequent in the short-term treatment of cervical pregnancies, Ushakov et al. (1996) reported that side-effects occurred 15% of the time. In view of the potential systemic side-effects and possible hazardous 2640 inducement of follicular growth of the ovaries, the administration of a relatively low dose of MTX must first be considered as the primary treatment.
Our observations showed that patients undergoing systemic administration of MTX tended to respond satisfactorily, compared with local injection or a combination of both methods, although the difference was not statistically significant. However, it is immature to draw a conclusion from this analysis because of the lack of a larger and well-designed study. Evidence from studies on the pharmacokinetic effects of MTX on tubal pregnancy showed that the injection of 1 mg/kg of MTX in the ectopic site appeared to be as effective as the systemic administration (i.m.) of MTX; the area under the curve was lower after the local injection than after the intramuscular injection of MTX, which may indicate a decrease in the bioavailability of MTX captured by target trophoblastic cells (Fernandez, et al., 1994) . Recently Nomiyama et al. (1997) developed a new MTX-lipiodol emulsion for local injection for salvage therapy in a case of cervical pregnancy that was refractory to intra-arterial embolization of the right descending uterine artery, intra-cardiac injection of potassium chloride and intra-amniotic instillation of 50 mg of MTX. They postulated that the promising result may be attributed to the emulsion containing MTX because it released slowly, increased the tissue concentration, and prolonged the drug effect. All these showed the potential advantages of local injection over systemic injection. However, the local intracellular MTX concentration was not being measured in peripheral blood samples. It was also not clear whether the local intracellular MTX concentration was relevant to the efficacy of therapy and whether the concentration in the trophoblastic tissue was really higher after the local injection than after the systemic administration (Schiff, 1992) . Thus, further studies and more clinical experience are needed to verify its role in the treatment of cervical pregnancy.
Our study also revealed another significant finding. That is, for a patient with a living cervical pregnancy, intracardiac injection of potassium chloride, intra-amniotic instillation of MTX or direct traumatic puncture to cease the embryonic cardiac activity is a meaningful procedure to decrease the potential risk of MTX treatment failure. In cases of tubal ectopic pregnancy, the presence of an embryonic cardiac activity was generally considered to be a contraindication (Ory, 1992) or relative contraindication (Carson and Buster, 1993) to conservative MTX therapy. Under actual conditions, feticide with intracardiac injection of potassium chloride was used as the primary therapy and also after failed systemic treatment in cervical pregnancy . Feticide can be performed more easily in cervical than tubal ectopic pregnancies under transvaginal sonographic guidance. Nevertheless, Marcovici et al. (1994) reported a case of cervical pregnancy that was treated with intra-amniotic injection of potassium chloride and MTX. The case, which later complicated into a gestational sac collapse during aspiration and perfuse bleeding, required surgical haemostasis. From our experience, we inserted a needle through the sac by means of the cervical wall instead of the cervical canal to keep the sac intact; the bleeding caused by the puncture was minimal and usually could be controlled by vaginal gauze packing (Hung et al., 1995) .
One problem that remains puzzling is the inability to predict the occurrence of massive bleeding with MTX treatment from this analysis. Six patients developed massive bleeding unexpectedly 4-28 days after initial MTX treatment. The bleeding could be the result of trophoblast-decidua shedding from the uninvolutional and atonic cervix because of the antimetabolic effect of MTX or tissue necrosis and sloughing from drug extravasation by local injection. Another major concern was the possibility of placenta accreta in which the trophoblastic tissue continues to proliferate (Monks et al., 1993) . This was also true, however, with conservative surgical procedures. There is still a need, therefore, to monitor the serum β-HCG levels and sonographic changes of the ectopic gestation following MTX administration.
Five patients underwent additional interventions for a persistent cervical ectopic gestation; of these, four preserved their potential fertility. The remaining patient received prostaglandin intra-amniotically and systemically to induce cervical ripening. Despite simultaneous curettage, intractable haemorrhage necessitated an emergency hysterectomy (Dall et al., 1994) . Our previous report, which involved a living cervical pregnancy successfully treated with intra-amniotic instillation of MTX, showed that the cervical mass containing gestational tissue may persist for a prolonged period and manifest in a relatively slow involution in size and echopattern sonographically despite the fact that the serum β-HCG concentration had become undetectable and normal menstrual cycles had returned (Hung et al., 1997) . In view of the potential risk of intractable haemorrhage, a slow regression in the ectopic gestation without evident embryonic cardiac activity, a rise or plateau of serum β-HCG level or massive bleeding should not be regarded as treatment failure. Waiting longer for MTX to take significant effect might be a more appropriate strategy for such patients.
Our study is subject to certain limitations, especially with regard to information and selection bias. Information bias seems unlikely because we took reliable information from the authors' descriptions of individual case reports. Although some data related to the potential determinants we studied were not available, these were noted only in a substantially small number of cases. It is also possible that there are some other prognostic 2641 factors that were not covered by the current study. However, the factors we reported here should be the most important and available for clinical practice according to our review and experience.
Selection bias may have led to a false low rate of unsatisfactory results of primary MTX treatment in cervical pregnancy. But unlike the problems encountered by other meta-analyses of trial studies, which usually favour a positive result, there seems no obvious reason related to the prognostic factors for the current study to publish these case reports. Thus, the validity of the analysis of these prognostic factors will be maintained. Furthermore, we adopted a more extensive definition of an unsatisfactory result and this should provide some protection against this source of bias. We also examined the distribution of the articles that we included, which was according to either the geographic localization or journal ranking, and found that there was no difference when they were compared with publications that were excluded or not related to MTX treatment. Moreover, the homogeneity test of odds ratios for the factors having significant association with the result of the primary MTX treatment analysed from the pooled data between our own 15 patients and the 37 patients from the reviewed literature revealed a consistent result. It therefore appears unlikely that such a selection would bias the magnitude of the association between the potential determinants we studied and an unsatisfactory result of primary MTX treatment.
In conclusion, data available in the literature and from the current analysis suggested that systemic administration of low dose MTX is ideal for patients who are clinically stable with cervical pregnancies of Ͻ9 weeks gestation and serum β-HCG concentrations Ͻ10 000 mIU/ml. If embryonic cardiac activity is evident, concomitant feticide must be performed to minimize the potential risk of MTX treatment failure.
